Abstract
Through facilitating DNA homologous recombination repair, PPIP5K2 has been proven to be essential for improving colorectal cancer survival in our previous research. However, its function in the tumorigenesis of NSCLC, the most common cancer and the primary cause of cancer-related death globally, is still unknown. Here, we initially discovered that PPIP5K2 had significant effects on proliferation of NSCLC cells through loss- and gain-of-function assays in vitro and in vivo. Moreover, PPIP5K2 is capable of regulating NSCLC cells metastasis in an EMT-dependent manner. In terms of mechanism exploration, we found that PPIP5K2 knockdown can significantly inhibit the phosphorylation of AKT/mTOR signaling pathway, whereas the overexpression of PPIP5K2 resulted in converse effects. By employing AKT signaling related agonists or antagonists, we further demonstrated that PPIP5K2 regulates NSCLC tumorigenesis partly via the AKT/mTOR pathway. In conclusion, PPIP5K2 plays a key oncogenic role in NSCLC by the activation of the AKT/mTOR signaling axis. It is anticipated that targeting PPIP5K2 might emerge as a viable therapeutic approach for NSCLC patients.
Funding Information
  • National Natural Science Foundation of China (82203331, 82300137, 92259102, CSTB2023NS CQ-MSX0065, JJZD2022–02, YXJL-2022-0435-0098, Y-HR2020ZD-0361)
  • Natural Science Foundation of Chongqing Municipality (82203331, 82300137, 92259102, CSTB2023NS CQ-MSX0065, JJZD2022–02, YXJL-2022-0435-0098, Y-HR2020ZD-0361)
  • Haiyan fund of Harbin Medical University Cancer Hospital (82203331, 82300137, 92259102, CSTB2023NS CQ-MSX0065, JJZD2022–02, YXJL-2022-0435-0098, Y-HR2020ZD-0361)
  • Beijing Medical Award Foundation (82203331, 82300137, 92259102, CSTB2023NS CQ-MSX0065, JJZD2022–02, YXJL-2022-0435-0098, Y-HR2020ZD-0361)
  • CSCO-Hengrui Tumor Research Fund (82203331, 82300137, 92259102, CSTB2023NS CQ-MSX0065, JJZD2022–02, YXJL-2022-0435-0098, Y-HR2020ZD-0361)

This publication has 41 references indexed in Scilit: